202 related articles for article (PubMed ID: 28094532)
1. Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties.
Siwowska K; Haller S; Bortoli F; Benešová M; Groehn V; Bernhardt P; Schibli R; Müller C
Mol Pharm; 2017 Feb; 14(2):523-532. PubMed ID: 28094532
[TBL] [Abstract][Full Text] [Related]
2. Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates.
Müller C; Guzik P; Siwowska K; Cohrs S; Schmid RM; Schibli R
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914162
[TBL] [Abstract][Full Text] [Related]
3. Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.
Benešová M; Guzik P; Deberle LM; Busslinger SD; Landolt T; Schibli R; Müller C
Mol Pharm; 2022 Mar; 19(3):963-973. PubMed ID: 35192367
[TBL] [Abstract][Full Text] [Related]
4. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
[TBL] [Abstract][Full Text] [Related]
5. (64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate.
Farkas R; Siwowska K; Ametamey SM; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2016 Jun; 13(6):1979-87. PubMed ID: 27145400
[TBL] [Abstract][Full Text] [Related]
6. Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy.
Haller S; Reber J; Brandt S; Bernhardt P; Groehn V; Schibli R; Müller C
Nucl Med Biol; 2015 Oct; 42(10):770-9. PubMed ID: 26162583
[TBL] [Abstract][Full Text] [Related]
7. Preclinical development of small-molecular-weight folate-based radioconjugates: a pharmacological perspective.
Siwowska K; Müller C
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):269-86. PubMed ID: 26149341
[TBL] [Abstract][Full Text] [Related]
8. Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-to-background contrast.
Reber J; Struthers H; Betzel T; Hohn A; Schibli R; Müller C
Mol Pharm; 2012 May; 9(5):1213-21. PubMed ID: 22509996
[TBL] [Abstract][Full Text] [Related]
9. Reduced
Boss SD; Müller C; Siwowska K; Büchel JI; Schmid RM; Groehn V; Schibli R; Ametamey SM
Bioconjug Chem; 2018 Apr; 29(4):1119-1130. PubMed ID: 29412638
[TBL] [Abstract][Full Text] [Related]
10. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
Müller C; Schubiger PA; Schibli R
Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
[TBL] [Abstract][Full Text] [Related]
11. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
12. Investigations Using Albumin Binders to Modify the Tissue Distribution Profile of Radiopharmaceuticals Exemplified with Folate Radioconjugates.
Busslinger SD; Becker AE; Vaccarin C; Deberle LM; Renz ML; Groehn V; Schibli R; Müller C
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686538
[TBL] [Abstract][Full Text] [Related]
13. Novel Synthetic Strategies Enable the Efficient Development of Folate Conjugates for Cancer Radiotheranostics.
Deberle LM; Benešová M; Becker AE; Ratz M; Guzik P; Schibli R; Müller C
Bioconjug Chem; 2021 Aug; 32(8):1617-1628. PubMed ID: 34251183
[TBL] [Abstract][Full Text] [Related]
14. Improved PET imaging of tumors in mice using a novel (18) F-folate conjugate with an albumin-binding entity.
Fischer CR; Groehn V; Reber J; Schibli R; Ametamey SM; Müller C
Mol Imaging Biol; 2013 Dec; 15(6):649-54. PubMed ID: 23760583
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
16. Comparative Studies of Three Pairs of α- and γ-Conjugated Folic Acid Derivatives Labeled with Fluorine-18.
Boss SD; Betzel T; Müller C; Fischer CR; Haller S; Reber J; Groehn V; Schibli R; Ametamey SM
Bioconjug Chem; 2016 Jan; 27(1):74-86. PubMed ID: 26634288
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy.
Müller C; Mindt TL; de Jong M; Schibli R
Eur J Nucl Med Mol Imaging; 2009 Jun; 36(6):938-46. PubMed ID: 19183997
[TBL] [Abstract][Full Text] [Related]
18.
Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
[TBL] [Abstract][Full Text] [Related]
19. Effects of antifolate drugs on the cellular uptake of radiofolates in vitro and in vivo.
Müller C; Brühlmeier M; Schubiger PA; Schibli R
J Nucl Med; 2006 Dec; 47(12):2057-64. PubMed ID: 17138750
[TBL] [Abstract][Full Text] [Related]
20. Tumor targeting using 67Ga-DOTA-Bz-folate--investigations of methods to improve the tissue distribution of radiofolates.
Müller C; Vlahov IR; Santhapuram HK; Leamon CP; Schibli R
Nucl Med Biol; 2011 Jul; 38(5):715-23. PubMed ID: 21718947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
